Orbimed Advisors LLC Adaptimmune Therapeutics PLC Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$2.58 - $12.1 $6.52 Million - $30.6 Million	-2,525,654 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $1.41 Million - $5.31 Million	1,174,999 Added 86.99%	2,525,654 $6.87 Million
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $2.57 Million - $9.69 Million	684,062 Added 102.62%	1,350,655 $7.77 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $2.08 Million - $2.75 Million	-200,000 Reduced 23.08%	666,593 $7.91 Million
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $7.44 Million - $12.1 Million	-1,048,067 Reduced 54.74%	866,593 $9.73 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $9.44 Million - $17.1 Million	1,914,660	1,914,660 $15.7 Million

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $121M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.